Where does HURA stock trade?

TuHURA Biosciences Inc. (HURA) is listed on NASDAQ.

What sector and industry is HURA in?

TuHURA Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

What are analysts saying about HURA?

TuHURA Biosciences Inc. has had 4 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $900.00 price target on 2026-04-27. Recent price targets range from $900.00 to $1500.00.

What companies are similar to HURA?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HURA side-by-side with any of them on Quantisnow.

How can I track HURA on Quantisnow?

Quantisnow aggregates TuHURA Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HURA to receive live email and push alerts on every new disclosure.

HURA

NASDAQ

TuHURA Biosciences Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings4

News · 26 weeks32+20%

2026-03-012026-08-23

Mix1690d

SEC Filings12(75%)
Other3(19%)
Insider1(6%)

Latest news

25 items

4dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
6dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
11dSEC
SEC Form 10-Q filed by TuHURA Biosciences Inc.
10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
11dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
11dPR
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update. "We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. James Bianco, President and CEO of TuHURA Biosciences. "In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating ou
12dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
27dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
34dPR
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the Canaccord Genuity's 46th Annual Growth Conference taking place in Boston, MA.Canaccord Genuity 46th Annual Growth ConferenceDate: Wednesday, August 12, 2026Time: 12:30pm ETTo register and view the presentation, please CLICK HERE. An archived webcast of the Canaccord presentation will be available on the Events Page in the Investor Section of T
47dSEC
SEC Form DEFA14A filed by TuHURA Biosciences Inc.
DEFA14A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
47dSEC
SEC Form DEF 14A filed by TuHURA Biosciences Inc.
DEF 14A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
49dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
60dSEC
SEC Form PRE 14A filed by TuHURA Biosciences Inc.
PRE 14A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
69dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Shareholder Director Nominations
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
71dPR
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML)The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026TAMPA, Fla., June 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeu
88dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
88dINSIDER
Chief Executive Officer Bianco James A. gifted 150,000 shares, decreasing direct ownership by 6% to 2,173,307 units (SEC Form 4)
4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)
102dSEC
SEC Form 10-Q filed by TuHURA Biosciences Inc.
10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
102dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
102dPR
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update."I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a $50 million non-equity-based source of operating capital in the form of credit facility with our largest stockholder on attractive terms for the company allowing us to fund operatio
105dPR
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat, at the 4th Annual H.C. Wainwright BioConnect Investor Conference taking place in New York City.4th Annual H.C. Wainwright BioConnect Investor ConferenceDate: Tuesday, May 19, 2026Time: 2:00 pm ETLinks: To register and view presentation, click HERE.A live and archived webcast of the presentation will also be available through the investors page of TuHU
117dSEC
Amendment: SEC Form 8-K/A filed by TuHURA Biosciences Inc.
8-K/A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
117dSEC
Amendment: SEC Form 10-K/A filed by TuHURA Biosciences Inc.
10-K/A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
120dANALYST
Citizens initiated coverage on TuHURA Biosciences with a new price target
Citizens initiated coverage of TuHURA Biosciences with a rating of Mkt Outperform and set a new price target of $9.00
125dSEC
TuHURA Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure
8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
125dPR
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestonesTAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses. The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC.Under the terms of the

HURA FAQ

5 questions

Where does HURA stock trade?
TuHURA Biosciences Inc. (HURA) is listed on NASDAQ.
What sector and industry is HURA in?
TuHURA Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
What are analysts saying about HURA?
TuHURA Biosciences Inc. has had 4 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $900.00 price target on 2026-04-27. Recent price targets range from $900.00 to $1500.00.
What companies are similar to HURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HURA side-by-side with any of them on Quantisnow.
How can I track HURA on Quantisnow?
Quantisnow aggregates TuHURA Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HURA to receive live email and push alerts on every new disclosure.